
|Articles|December 12, 2012
Implant not recommended in UK, but to be launched in European market
The fluocinolone acetonide intravitreal implant (Iluvien, Alimera) has not met the UK’s cost-effectiveness thresholds for treating DME. Alimera has, however, signed an agreement with Quintiles for the implant’s European launch.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection
5





















